File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Relapse prevention in first-episode psychosis patients with stable maintenance medication for at least one year

TitleRelapse prevention in first-episode psychosis patients with stable maintenance medication for at least one year
Authors
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://schizophreniabulletin.oxfordjournals.org/
Citation
The 12th International Congress on Schizophrenia Research (ICOSR), San Diego, CA., 28 March-1 April 2009. In Schizophrenia Bulletin, 2009, v. 35 suppl. 1, p. 347, ID: 550243 How to Cite?
AbstractClinically there is a strong expectation from first-episode psychosis patients and their carers to discontinue with maintenance medication after a period of remission. However, there is so far no consensus regarding how long maintenance medication should be continued. The current study aims to assess whether this point in time is reached after at least 1 year of maintenance medication. Following a first-episode of schizophrenia and non-affective psychosis (DSM-IV), patients who were remitted well and on maintenance medication for at least 12 months were randomized to receive either maintenance medication (quetiapine 400mg/day) or placebo. Relapse was defined as the re-emergence of positive symptoms. In the overall sample of 178, 83 patients relapsed during the study. Fewer patients relapsed in the quetiapine maintenance group (27 of 89, 30%) compared with the placebo group (56 of 89, 63%). The Kaplan-Meier estimate of the proportion of relapse at 11 months after randomization was 41 percent (95% CI, 29 to 53%) in the quetiapine maintenance group and 76 percent (95% CI, 66 to 86%) in the placebo group (log-rank test, v2 = 15.65, P < .001). New data for relapse risks in remitted first-episode psychosis patients is provided. The risk of relapse after medication discontinuation is still substantial after receiving maintenance medication for a mean of 22 months following first-episode psychosis. Supported by investigator initiated trial award from AstraZeneca and the Research Grants Council Hong Kong (Project number: 765505).
Description22. 22. Therapeutics: Treatment Trials
Abstracts for the 12th International Congress on Schizophrenia Research (ICOSR)
Persistent Identifierhttp://hdl.handle.net/10722/62691
ISSN
2015 Impact Factor: 7.757
2015 SCImago Journal Rankings: 4.051
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChen, EYHen_HK
dc.contributor.authorHui, CLMen_HK
dc.contributor.authorLam, MLMen_HK
dc.contributor.authorLaw, CWen_HK
dc.contributor.authorChiu, CPY-
dc.contributor.authorChung, D-
dc.contributor.authorTso, S-
dc.contributor.authorPang, E-
dc.contributor.authorChan, KT-
dc.contributor.authorWong, YC-
dc.contributor.authorChan, K-
dc.contributor.authorHung, SF-
dc.contributor.authorYau, T-
dc.contributor.authorHoner, WG-
dc.date.accessioned2010-07-13T04:06:59Z-
dc.date.available2010-07-13T04:06:59Z-
dc.date.issued2009en_HK
dc.identifier.citationThe 12th International Congress on Schizophrenia Research (ICOSR), San Diego, CA., 28 March-1 April 2009. In Schizophrenia Bulletin, 2009, v. 35 suppl. 1, p. 347, ID: 550243en_HK
dc.identifier.issn0586-7614en_HK
dc.identifier.urihttp://hdl.handle.net/10722/62691-
dc.description22. 22. Therapeutics: Treatment Trials-
dc.descriptionAbstracts for the 12th International Congress on Schizophrenia Research (ICOSR)-
dc.description.abstractClinically there is a strong expectation from first-episode psychosis patients and their carers to discontinue with maintenance medication after a period of remission. However, there is so far no consensus regarding how long maintenance medication should be continued. The current study aims to assess whether this point in time is reached after at least 1 year of maintenance medication. Following a first-episode of schizophrenia and non-affective psychosis (DSM-IV), patients who were remitted well and on maintenance medication for at least 12 months were randomized to receive either maintenance medication (quetiapine 400mg/day) or placebo. Relapse was defined as the re-emergence of positive symptoms. In the overall sample of 178, 83 patients relapsed during the study. Fewer patients relapsed in the quetiapine maintenance group (27 of 89, 30%) compared with the placebo group (56 of 89, 63%). The Kaplan-Meier estimate of the proportion of relapse at 11 months after randomization was 41 percent (95% CI, 29 to 53%) in the quetiapine maintenance group and 76 percent (95% CI, 66 to 86%) in the placebo group (log-rank test, v2 = 15.65, P < .001). New data for relapse risks in remitted first-episode psychosis patients is provided. The risk of relapse after medication discontinuation is still substantial after receiving maintenance medication for a mean of 22 months following first-episode psychosis. Supported by investigator initiated trial award from AstraZeneca and the Research Grants Council Hong Kong (Project number: 765505).-
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://schizophreniabulletin.oxfordjournals.org/en_HK
dc.relation.ispartofSchizophrenia Bulletin-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleRelapse prevention in first-episode psychosis patients with stable maintenance medication for at least one yearen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.emailHui, CLM: clmhui@hkusua.hku.hken_HK
dc.identifier.emailLam, MLM: maylam11@hku.hken_HK
dc.identifier.emailChiu, CPY: chiupyc@hku.hken_HK
dc.identifier.authorityChen, EYH=rp00392en_HK
dc.identifier.authorityLam, MLM=rp00296en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/schbul/sbn173-
dc.identifier.pmid19252181-
dc.identifier.pmcidPMC2651108-
dc.identifier.hkuros163062en_HK
dc.identifier.volume35-
dc.identifier.issuesuppl. 1-
dc.identifier.spage347, ID: 550243-
dc.identifier.epage347, ID: 550243-
dc.identifier.isiWOS:000263964700003-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats